Table 3.
Estimates of completeness of each source (model 7)
|
Strata |
|
Total |
DOVIH |
EPF |
LaboVIH |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (95% CI) | Nobs | Compl(%) | (95% CI) | Nobs | Compl(%) | (95% CI) | Nobs | Compl(%) | (95% CI) | Nobs | Compl(%) | (95% CI) | ||
| Year of diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2003 |
107 |
(72.4;142.7) |
60 |
55.8 |
(42.0:82.9) |
30 |
27.9 |
(21.0;41.4) |
28 |
26.0 |
(19.6:38.7) |
30 |
27.9 |
(21.0;41.4) |
| 2004 |
99 |
(68.9;129.4) |
59 |
59.5 |
(45.6;85.7) |
35 |
35.3 |
(27.0;50.8) |
32 |
32.3 |
(24.7;46.5) |
35 |
35.3 |
(27.0;50.8) |
| 2005 |
91 |
(62.4;120.9) |
53 |
57.8 |
(43.8;85.0) |
27 |
29.5 |
(22.3;43.3) |
27 |
29.5 |
(22.3;43.3) |
34 |
37.1 |
(28.1;54.5) |
| 2006 |
88 |
(55.4;121.8) |
44 |
49.7 |
(36.1;79.4) |
18 |
20.3 |
(14.8;32.5) |
14 |
15.8 |
(11.5;25.3) |
30 |
33.9 |
(24.6;54.2) |
| Place of birth |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| France |
152 |
(100.3;204.9) |
86 |
56.4 |
(42.0;85.7) |
37 |
24.2 |
(18.1;36.9) |
47 |
30.8 |
(22.9;46.8) |
55 |
36.0 |
(26.8;54.8) |
| Foreign country |
234 |
(158.9;309.9) |
130 |
55.5 |
(42.0;81.8) |
73 |
31.1 |
(23.6;45.9) |
54 |
23.0 |
(17.4;34.0) |
74 |
31.6 |
(23.9;46.6) |
| Region of diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Paris area |
198 |
(154.7;241.4) |
139 |
70.2 |
(57.6;89.9) |
79 |
39.9 |
(32.7;51.1) |
79 |
39.9 |
(32.7;51.1) |
82 |
41.4 |
(34.0;53.0) |
| Other regions |
188 |
(101.0;276.8) |
77 |
40.8 |
(27.8;76.2) |
31 |
16.4 |
(11.2;30.7) |
22 |
11.6 |
(7.9;21.8) |
47 |
24.9 |
(17.0;46.5) |
| Total | 387 | (271;503) | 216 | 55.8 | (42.9;79.7) | 110 | 28.4 | (21.9;40.1) | 101 | 26.1 | (20.1;37.3) | 129 | 33.3 | (25.6;47.6) |
DOVIH: Mandatory HIV case reporting; EPF: ANRS French Perinatal Cohort; LaboVIH: Laboratory surveillance of HIV testing activity.
: Estimate of the number of diagnoses; Nobs: Number of diagnoses observed; Compl: Completeness; 95% CI: 95% confidence interval for completeness.